Bluebird Bio Shouldn't Be Blue About Celgene's Juno Deal: Gadfly


Celgene Corp.'s $9 billion purchase of Juno Therapeutics Inc. might have Bluebird Bio Inc. feeling like a third wheel. The deal announced on Monday means Bluebird -- which, like Juno, is working on so-called cell therapies that train human immune cells to hunt cancer -- likely loses its most obvious potential deal suitor.



from Biotech News